Masila, thanks for this.

This is the kind of information that keeps me long on RVX and excited about the potential of Zenith.

One question it raises is I wonder, based on the last paragraph, why Don has not been successful in licensensing out various compounds for other biotechs to take into trials. Perhaps that is not a priority? Or there is no interest. If no interest then why?

I wonder why Zenith has not leveraged this in a PR context to build interest in this company? It does not appear that Don has any interest in providing liquidity to shareholders at this stage so from that perspective it is irrelevant. 

Assuming that "Genetic Engineering & Biotechnology News" is a legitimate publication and that the article was not bought by RVX/Zenith it really is a shame that this information is not being showcased.

On a separate point I wonder if/when we'll receive an update on the zen3694 trial?

In the Q & A at either Zenith or RVX Don was asked if he is overstretched (doing both the Zen and RVX CEOs) and he said everything is running smoothly or something to that effect. I sense he is overstretched. How could he have the time to deal with all of the opportunities in both companies?

Oh well let's hope the trial shows some promise.

GLTA

Toinv